David Cella

ORCID: 0000-0002-9881-4541 · 2 papers in corpus

rct 2014

Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group

Journal of Clinical Oncology ·doi:10.1200/jco.2014.55.6993

PURPOSE: The effects of ovarian function suppression (OFS) on survival and patient-reported outcomes were evaluated in a phase III trial in which premenopausal women were randomly assigned to tamoxifen with or without OFS. PATIENTS AND MET…

nonrandomized-trial 2012

The FACIT-AI, a new tool for assessing symptoms associated with malignant ascites

Gynecologic Oncology ·doi:10.1016/j.ygyno.2012.11.013

OBJECTIVE: The objectives of this study are to assess the clinical relevance and validity of the Functional Assessment of Chronic Illness Therapy-Ascites Index (FACIT-AI) in women with ovarian cancer and malignant ascites, and to modify the…